Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population
- PMID: 25932390
- PMCID: PMC4366773
- DOI: 10.4103/2230-8210.152771
Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population
Abstract
Introduction: Prolactinomas are less frequent, but more invasive in males. Giant ones (≥4 cm) are extremely rare in literature. Their neurological, psychiatric and endocrine complications are life threatening. Our aim was to report the largest mono center series in order to analyze their frequency, their characteristics, and their complications.
Subjects and methods: All patients had clinical examination, hormonal, ophthalmological, and radiological assessment based on computed tomography scan and cerebral magnetic resonance imaging. Positive diagnosis was based on clinical symptoms, high prolactin ± immunohistochemy study. Mixed adenomas were excluded by hormonal exploration and immunohistochemy. For those who received medical treatment only, a reduction in tumor size was considered a supplementary positive point for the diagnosis.
Results: Among 154 male prolactinomas seen between 1987 and 2013, we observed 44 giant tumors (28.5%). Median age = 36 years, and 38.3% were under 30. Median tumor height = 53.95 mm (40-130) and median prolactin = 15,715 ng/ml (n < 20). Solid and cystic aspect ± calcifications was observed in 25%. 42 had cavernous sinuses invasion. Other invasions were: Posterior= 65.9%, anterior= 63.6%, temporal= 15.9% and frontal = 9%. For endocrine complications: Hypogonadism = 98.4%, thyrotroph and corticotroph deficits were seen in respectively 34%, and 32%. Posterior pituitary insufficiency was observed in one case. For ophthalmological complications: Optic atrophy = 46%, Ptosis = 6.8%, diplopia/strabismus = 4.5%. Neurological complications were: Memory loss and/or unconsciousness = 18.2%, epilepsy = 15.9%, frontal syndrome = 9% and obstructive hydrocephalus = 6.8%.
Conclusion: Giant prolactinomas account for 28% in our population. Severe neurological complications are frequent. But, obstructive hydrocephalus is rare, which argues for a slow progression.
Keywords: Giant prolactinomas; male; neurological life threatening complications; optic atrophy; pituitary insufficiency.
Conflict of interest statement
Similar articles
-
Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.Clin Med Insights Endocrinol Diabetes. 2020 Jun 4;13:1179551420926181. doi: 10.1177/1179551420926181. eCollection 2020. Clin Med Insights Endocrinol Diabetes. 2020. PMID: 32547285 Free PMC article.
-
Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma.Clin Med Insights Case Rep. 2012;5:115-8. doi: 10.4137/CCRep.S9675. Epub 2012 Jul 16. Clin Med Insights Case Rep. 2012. PMID: 22855635 Free PMC article.
-
Long-term outcome of multimodal therapy for giant prolactinomas.Endocrine. 2017 Jan;55(1):231-238. doi: 10.1007/s12020-016-1129-9. Epub 2016 Oct 4. Endocrine. 2017. PMID: 27704480
-
Giant Prolactinomas.Neuroendocrinology. 2019;109(1):51-56. doi: 10.1159/000495184. Epub 2018 Nov 7. Neuroendocrinology. 2019. PMID: 30404098 Review.
-
Therapy of endocrine disease: the challenges in managing giant prolactinomas.Eur J Endocrinol. 2014 Jun;170(6):R213-27. doi: 10.1530/EJE-14-0013. Epub 2014 Feb 17. Eur J Endocrinol. 2014. PMID: 24536090 Review.
Cited by
-
Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.Clin Med Insights Endocrinol Diabetes. 2020 Jun 4;13:1179551420926181. doi: 10.1177/1179551420926181. eCollection 2020. Clin Med Insights Endocrinol Diabetes. 2020. PMID: 32547285 Free PMC article.
-
Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1.Front Endocrinol (Lausanne). 2019 Aug 28;10:582. doi: 10.3389/fendo.2019.00582. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31555208 Free PMC article.
References
-
- Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–88. - PubMed
-
- Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156–8. - PubMed
-
- Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. Eur J Endocrinol. 2009;160:747–52. - PubMed
-
- Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett. 2005;26:152–9. - PubMed
-
- Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, et al. Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol. 2002;15:1357–65. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources